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Chapter 1 
 
INTRODUCTION 
 
“Drugs don’t work in patients who don’t take them” 
– General C. Everett Koop (Ho, Bryson, Rumsfield, 2009)  
 
Statement of Problem 
 
 In the United States, 33 to 69% of all medication-related hospital 
admissions are due to poor medication adherence (Bissonette, 2008). This poor 
adherence results in a cost of approximately $100 billion a year (Drotar, 2010). 
Medication adherence is important to the health of patients and cost containment 
in healthcare which impacts society as a whole. Lack of adherence increases 
hospital admissions and disease complications, worsens health outcomes, 
decreases quality of life, and ultimately impacts mortality (Quine, 2012; Gellard, 
Grenard, & McGlynn, 2009; De Civita, 2005). Often, medication regimens are 
intensified due to un-identified non-adherence; this produces unnecessary side 
effects and potential harm to patients.  
Rates of non-adherence have been reported as 50% overall in pediatric 
patients (Drotar, 2010). These rates are typically higher in chronic disease when 
compared to acute illnesses (Drotar, 2010; La Greca, 1990). Reasons for non-
adherence are multifactorial. The most important determinants of non-adherence 
are consistently documented as complexity and duration of treatment regimens 
(Quine, 2012; Varni, 1984). Patients undergoing difficult pediatric hematopoietic 
stem cell transplants (HSCT) that require life-long medication are high risk for 
medication non-adherence. 
Hematopoietic stem cell transplant. HSCT is the transplantation of 
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hematopoietic stem cells derived from bone marrow (i.e. ‘bone marrow 
transplant’ [BMT] or peripheral blood stem cells [PBSC]). HSCT became the 
common treatment for life-threatening malignant (e.g., acute leukemia, 
lymphoma) and non-malignant (e.g., aplastic anemia, sickle cell disease, 
thalassemia, immune deficiencies, genetic disorders) disorders in the mid1900s. 
Prior to undergoing life-saving HSCT, many children endure lengthy, aggressive 
treatment aimed at curing their original disease only to experience treatment 
failure or relapse.  
Bone marrow transplant is a complex procedure with high mortality rates. 
The process can be physically and emotionally difficult for children and their 
parent caregivers. Recipients of bone marrow transplants need to adhere to 
multifaceted outpatient regimens that require strict personal hygiene, 
environmental restrictions and complex medication regimens. Lack of adherence 
to any of these regimens can be life threatening (Hoodin, 1993). Adherence to 
immunosuppressant medications during the acute phase (first 100 days) post-
transplant is critical to prevent graft versus host disease (GVHD) and avoid graft 
failure.  
Graft vs. Host Disease. Moderate to severe acute GVHD develops in 40 
to 50% of patients undergoing allogeneic HSCT (Weisdorf et al., 1990; Roy et al., 
1992 ). Acute GVHD most often occurs in the first 100 days post transplant. 
Pediatric patients that develop acute GVHD have a 30 to 50% chance of survival 
(Jacobsohn, 2008). Clinicians and researchers are focused on GVHD prevention 
to minimize unnecessary treatment related deaths, however, results are poor. 
The most commonly used prevention therapy is a combination of calcineurin 
	 3	
inhibitor (CNI) and methotrexate. Standard calcineurin inhibitors are tacrolimus 
and cyclosporine. CNI therapy is required for at least 100 days post-transplant to 
prevent GVHD and used lifelong in solid organ transplant (SOT) to prevent graft 
rejection (Pavletic & Fowler, 2012).These medications can be challenging to 
administer to children as they require two to three times a day dosing, are foul-
smelling and taste bitter. An estimated rate of 40 to 70% non-adherence could 
significantly be contributing to the unacceptable rates of GVHD and death. 
Despite these factors, adherence in hematopoietic stem cell transplant is 
understudied and contributing factors to non-adherence are not fully understood.  
Outcomes. The societal burden of cancer care and HSCT is substantial 
and likely to increase based on the growing number of transplants each year 
(Khera, Zeliadt, Lee, 2012). Figure 1 depicts the relationship between non-
adherence, poor outcomes and increased healthcare utilization and cost. 
Prevention and better management of HSCT complications may improve clinical 
outcomes, reduce cost and minimize resource utilization. Adherence may have a 
significant role in increasing life expectancy and quality of life for children and 
families enduring HSCT. Increased adherence could reduce readmissions, 
decrease adverse events and side effects, and ultimately increase quality of life 
and outcomes for pediatric HSCT patients.  
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Figure 1. Conceptual diagram illustrating relationships among non-adherence, 
poor outcomes and increased cost.  
 
Adherence in pediatric hematopoietic stem cell patients.  To date, 
only three pediatric studies are known that examine adherence in the 
hematopoietic stem cell transplant population. The adherence rate in these three 
studies range from 52 to 73% (Phipps & Decuir-Whalley 1990; McGrady, 
Williams, Davies & Pai 2014; Pai et al 2018). One study was a retrospective 
chart review of inpatients (n=54), the other two were outpatient prospective 
studies, one focused on adolescents (n=6).  Both prospective trials used 
electronic pill bottle monitors for measurement of adherence (McGrady, Williams, 
Davies & Pai 2014; Pai et al 2018).  McGrady et al (2014) found of the 6 
adolescents the adherence rate was approximately 73%, but declined over time. 
At least one dose of medication was missed approximately 3 days a week. 
Although small numbers, the results of this study suggest adherence in the 
pediatric HSCT population is poor. Pai et al (2018) was the only study to examine 
Nonadherence	to	immunosuppressants	
Development	of	GVHD		
Increased	complexity	of	treatment	regimen,		side	effects,	length	of	therapy	
Increased	health	care	costs	
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the relationship of adherence to adverse outcomes and found that poor 
adherence to oral medications was associated with an increased incidence of 
infections during the outpatient treatment phase (p<.005). The adherence rate of 
these 50 outpatients was 63% at one month, but also declined over time, 
resulting in an adherence rate of 57% at six months. None of the studies 
examined adherence to only immunosuppressant medications.  
Adherence measurement.  There is no established “gold standard” to 
measure pediatric immunosuppressant adherence. Subjective self-report 
measures are commonly used in adherence research (Stirratt et al., 2015). Solid 
organ literature uses combination of measures to increase diagnostic accuracy 
(Frederick., 2008; Schafer-Keller,  2008). Shemesh et al (2004) describe the 
standard deviation method of tacrolimus as an indicator of adherence as well as 
a prediction of graft failure. Additional work in this area resulted in the 
development of the medication level variability index (MLVI) biomarker. The MLVI 
reflects the degree of variability between individual measures (Suplena et al 
2014). Preliminary work suggests standard deviations of tacrolimus assays may 
also have clinical utility in the pediatric HSCT population. Further validation, 
reliability, and correlations with outcomes are needed in the pediatric HSCT 
population.  
Theoretical framework 
 
 Theoretical models utilize established relationships to develop general 
principles that may describe a phenomenon (Johnston & Pennypacker, 1993). 
Approximately 80% of adherence literature has been described as atheoretical 
(Burkhart & Dunbar-Jacob, 2002). Despite this fact, several theories have been 
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used in the study of medication adherence. The most commonly used theories in 
chronic illness include the Health Belief Model (HBM), Social Cognitive Theory 
(SCT), Self-Efficacy Theory, Theory of Planned Behavior (TPB) and 
Transtheoretical Model (Drotar, 2010). Research utilizing these theories in 
pediatric adherence is limited, however, one known theory specific to pediatric 
adherence is the Pediatric Self-Management Model (PSM). 
The PSM (Figure 2) is a developmental ecological model, describing not 
only the individual, family and health care system but also the unique community 
domain (Modi et al., 2012). Developed specifically for the study of adherence in 
pediatric chronic illness, the model has the capability to guide the design and 
implementation of clinical interventions targeted at promoting self-management 
and treatment adherence. Although used in other pediatric chronic diseases, the 
PSM corresponds with potential risk factors to pediatric adherence in HSCT.  
Self-management in chronic illnesses is defined as the interaction of 
health behaviors and related processes that patients and families participate in to 
treat the chronic conditions (Modi et al., 2012). Ineffective self-management can 
reduce the prospective benefits of treatment. The PSM model is a wide-ranging 
ecological model comprised of four main domains; the individual, family, 
community and health care system. Within each domain, modifiable and non-
modifiable variables are identified. The model was developed due to limitations in 
previously discussed frameworks including lack of comprehensiveness, lack of 
generalizable frameworks in chronic illness, and absence of family and 
healthcare systems in adult theory (Ryan, 2009). The model drew from two well-
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established theories, the Ecological Systems Theory (EST) (Bronfenbrenner, 
1977) and the Health Belief Model (HBM) (Becker, 1974; Modi, 2012). 
   
 
 
Figure 2. Pediatric Self-Management Model. Modi et al., 2012. Pediatric 
Self-Management: A framework for research, practice and policy. Pediatrics, 129 
(2).  
 
The individual (microsystem) interacts with the family and community 
influences (mesosystem) and is based on the health care system influences 
(macrosystem). The HBM was used to describe the link between health 
behaviors, perception and self-management. Psychological symptoms, family 
involvement and knowledge of treatment regimens are considered modifiable or 
adaptable. However, chronicity of disease, age and gender are non-modifiable or 
non-adaptable. Each domain is directly affected by the child’s developmental 
level. Modifiable and non-modifiable variables as well as processes and 
behaviors are defined within each domain (Modi, 2012).  
Overall the model has a considerable number of strengths. Perhaps the 
greatest strength of the PSM is that it was specifically developed for describing 
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adherence in the pediatric chronic illness population. Subsequently, a distinct 
relationship between adherence and the effect on outcomes is well illustrated. 
Key concepts as well as domains within the PSM model are very thoroughly 
defined. Four domains are included and have potential to influence overall 
adherence.The model also includes the unique aspect of the community domain 
comprised of school, peers, neighborhoods and interpersonal networks. The 
model encompasses clinical practice, research, education, administration and the 
health care system. The model takes into consideration developmental levels, 
and therefore can be used across the continuum of the disease. Overall the PSM 
model is a distinct, comprehensive systems-based model designed to provide a 
testable framework in pediatric chronic disease. In addition to the 
comprehensiveness, the major strength of the PSM model is the well-defined 
outcome construct of adherence. 
Limitations of the PSM are related to the longitudinal applicability of the 
model in chronic illness. The direct relationships between each domain are also 
ambiguous. Few studies have used the model, therefore it is difficult to specify 
relationships between modifiable and non-modifiable factors.  
The PSM specifically addresses adherence within the chronic illness 
population and takes into account additional factors such as the family, the health 
care system and the community. Utilizing this theory to examine adherence in the 
pediatric HSCT population provides the opportunity to study each factor (e.g., 
family, healthcare system, community/social support) systematically and offers 
the most comprehensive description of adherence with opportunities to guide 
future interventions.  
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Adherence Correlates  
      Adherence is a continuum and reasons for non-adherence multifactorial 
(Reach, 2008). Pediatric adherence is complex and includes the entire family. 
Research and understanding of the family context, dynamics and relationships in 
association with medication adherence is necessary (Shellmer et al., 2011). 
Identifying the reasons patients and families do not adhere to medication 
regimens can guide future research and development of intervention trials aimed 
at improving overall adherence. Correlates are important to adherence research 
for many reasons: 1) they can be used to identify patients likely to be non-
adherent, 2) modifiable correlates can direct intervention studies, and 3) they aid 
in analysis and development of theories designed to describe adherence (Figure 
3) (M. A. Rapoff, 2010). The most commonly studied correlates in pediatric 
adherence are patient, family, disease and treatment factors. A description of 
these correlates and implications is described below.  
Child/Family correlates. Several child and family factors have been 
associated with adherence. Demographics, patient and caregiver knowledge of 
disease and medications, as well as family structure and coping, are cited in the 
literature as contributing to adherence in pediatric chronic illness. Adherence is 
directly influenced by demographic characteristics. Adolescents with chronic 
illness are more likely to be more non-adherent than younger children (Dew et 
al., 2009; De Geest & Dobbels, 2010; Fredericks, 2009; Fredericks et al., 2008; 
Germani et al., 2011). Gender as a correlate has mixed results. Some studies in 
cystic fibrosis and diabetes have found males to be less adherent (Lorenz, 
Christensen & Pichert, 1985;  Naar-King et al., 2006), while other studies in 
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diabetes and solid organ transplant have found females to be more non-adherent 
(Rapoff,  2010). Lower adherence is also reported in minority groups (McQuaid et 
al., 2003, Snodgrass et al., 2001). In pediatric chronic illness, lower income and 
lower parental education levels have been associated with non-adherence 
(Denson-Lino, Wilies-Jacobo, Rosas, O’Connor & Wilson, 1993; Rapoff et al., 
2005; Rapoff, 2010). 
  The correlation between knowledge and adherence varies. Increased 
parental knowledge showed higher adherence in children, however, level of 
knowledge did not contribute to adherence in adolescents (La Greca et al., 1990, 
Jensen et al., 2005). In patients with cancer, cystic fibrosis and diabetes, less 
knowledge is correlated with less adherence (La Greca et al., 1990, Tebbi et al., 
1986, Holmes et al., 2006, Rapoff, 2010). Knowledge did not correlate with 
adherence in adolescents with asthma or renal disease (Beck et al., 1980, 
McQuaid et al., 2003).  
Family structure is also associated with adherence. Divorce has been 
correlated with lower adherence to immunosuppressive medications after solid 
organ transplant (Shemesh et al., 2004). Additionally size of the family affects 
adherence. Patients with cancer from larger families have been reported less 
likely to be adherent (Tebbi et al., 1986). Primary responsibility of medication and 
treatment regimens, have also contributed to adherence. Low parental 
monitoring and vaguely defined roles and responsibilities have correlated to 
lower adherence (Beck et al., 1980; Feinstein et al., 2005; Holmes et al., 2006; 
Wiebe et al., 2005; Rapoff, 2010).  
Coping is consistently linked with adherence. Coping at the patient level, 
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as well as within the family unit, influences adherence (Rapoff, 2010; Naar-King 
et al., 2006; La Greca et al., 1995). Patient coping positively and negatively 
affects adherence. Higher self-esteem and perceived autonomy and 
independence have been associated with increased adherence in pediatric 
chronic illness (Friedman et al., 1986; Litt, Cuskey & Rosenberg, 1982). In 
patients with diabetes, high social functioning, internal locus of control, better 
problem-solving skills and disease specific adjustment have been associated 
with higher adherence (Jacobson et al., 1987; Rapoff, 2010). Self-reported 
optimism and hope have been correlated with improved adherence in cystic 
fibrosis and asthma patients (Gudas et al., 1991, Berg et al., 2007). Conflicting 
reports have emerged from cancer, diabetes and chronic renal disease patients. 
Emotional or behavioral problems within these disorders are less likely to adhere 
to prescribed regimens (Jacobson et al., 1987; Greening et al., 2007; Kennard et 
al., 2004; Miller & Drotar, 2003; Naar-King et al., 2006; Penkower et al., 2003). 
Cancer patients reporting the use of denial as coping were also found to have 
poor adherence (Tamaroff, Festa, Adesman & Walco, 1992). HIV patients with a 
history of substance abuse, stressful life events or dropping out of school have 
documented lower adherence (Williams et al., 2006). 
 Several coping correlates within the family are directly associated with 
increased adherence. Family support, cohesion, organization, expressiveness 
and family integration are positive correlates identified in pediatric chronic 
illnesses such as cystic fibrosis, diabetes, seizure disorders and renal disease 
(Friedman et al., 1986, La Greca et al., 1995; McCaul et al., 1987; Rapoff, 2010). 
In diabetes and asthma patients, superior communication and problem solving 
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have been correlated with higher adherence. Increased paternal involvement is 
also associated with increased adherence (Wysocki & Gavin, 2006).  
 Self-reported parental stress, parental depression and poor parental 
coping are variables known to contribute to decreased adherence (Bartlett et al., 
2004; Gerson et al., 2004; Wynn & Eckel, 1986). In diabetes and renal disease, 
poor communication and negative interactions between parent-child are 
associated with lower adherence (Gerson et al., 2004; Lewandowski & Drotar, 
2007; Miller & Drotar, 2007). Interestingly in cystic fibrosis, increased family 
social activities and greater marital satisfaction were found to correlate with 
worse adherence (Geiss et al., 1992; Patterson, 1985).  
Disease correlates. Several disease factors are associated with 
adherence. These factors include treatment duration, disease severity and 
complexity of regimen. The duration of treatment has been reported to affect 
adherence. Pediatric chronic illness is correlated with higher non-adherence 
rates than acute illness (Rapoff, 2010). Diseases such as diabetes, Juvenile 
Rheumatoid Arthritis (JRA), solid organ transplant, HSCT and asthma have all 
shown lower rates of adherence as time elapsed (Germania et al., 2011;Litt & 
Cuskey, 1982; Bronwnbridge & Fielding, 1994; Bond et al .,1992, McGrady et al., 
2014). Specific to HSCT, the most recent study in adolescent patients reported a 
steady decline in adherence rates from 90% at one month post discharge to 60% 
at 6 months post discharge (McGrady, Williams, Davies, Pai, 2014).  
High disease severity has been directly linked to lower adherence and 
increased health problems in a number of patients (Feldman et al., 2007, 
Brownridge & Fielding, 1994). To the contrary in the sickle cell population, more 
	 13	
frequent hospital admissions are linked to higher adherence (Barakat et al., 
2002). The relationship between adherence and disease severity remains 
unclear. Lack of adherence could increase disease severity; however on the 
contrary, severity of the disease could affect the likelihood of adherence. 
Treatment regimen complexity has also been associated with poor 
adherence. An increased total number and frequency of medications is directly 
correlated with lower adherence (Rapoff,  2010, April et al., 2008, Feldman et al., 
2007, Van Dyke et al., 2002). In addition, the burden of time and number of side 
effects of the prescribed treatment also influence adherence. Taste of 
medications and adverse side effects have been correlated to decreased 
adherence (Celano et al., 1998; Rapoff, 2010).  
Healthcare correlates. Often overlooked, healthcare providers and health 
systems have a significant influence on adherence (Sherbourne et al., 1992; 
Haynes et al., 1979). Contention between patient and physician leads to lower 
satisfaction and decreased adherence to the prescribed treatment regimen 
(Jimmy & Jose, 2011). A patient and family’s poor relationship with the provider 
and cost of care are the most common reasons for non-adherence attributed to 
the healthcare system (Iuga  & McGuire, 2014; DiMatteo, 2004).  
          Significant influences on adherence in pediatric patients with chronic 
illness are associated with healthcare provider relationships. Behaviors such as 
providing information, communicating with the child and family, as well as 
prescribing treatment have been identified as positive influences on adherence 
(De Civita,&  Dobkin, 2004; Nobile & Drotar, 2003, Drotar, 2009) . Parent-
provider communication has been correlated with greater satisfaction and 
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increased adherence (Nobile, Drotar, 2003, Aujoulat et al., 2011). In a review 
conducted by Drotar (2009), parents and children perceived provider 
communication as underemphasizing treatment adherence. Aujoulat et al. (2011) 
found that only 13% of providers recognized a shared responsibility in non-
adherent behaviors. In contrast, DiMatteo (2004) reported a link between positive 
child, parent and provider communication and adherence to treatment. Shared 
decision- making between provider, child and caregiver also fosters treatment 
adherence (Drotar, Crawford, Bonner, 2010). Lack of provider education related 
to the chronic illness and prescribed treatment has been shown to lead to 
knowledge deficits and subsequent non-adherence (Drotar, 2009).  
  Little is known about the relationship between the cost of care and 
adherence. Bender et al., (2006) found lower medication costs directly correlated 
with higher adherence in children with asthma. A literature review examining the 
relationship between cost and adherence revealed that 85% of the studies 
reported an increase in patient costs was significantly associated with non-
adherence (Eaddy et al., 2012). In a survey of 10,000 people, a higher drug cost 
was the 3rd most common reason for non-adherence (Boston Consulting Group, 
2003). Lack of prescription drug coverage has been associated with a fourfold 
increase in the likelihood of non-adherence (Matsui 2013; Law et al., 2012). 
         Discussion. Several correlates (Figure 3) influence adherence in the 
pediatric chronic illness population. The addition of family and parental correlates 
further complicate adherence in this susceptible group. Parental involvement is 
an essential factor in adherence (De Civita & Dobkin, 2005). Both child and 
parent caregiver treatment-related behaviors including division of treatment 
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responsibility must be taken into consideration. Health system factors include the 
provider relationship with the child as well as the caregiver. Much of the cost -
related non-adherence research is in adults; further study related to pediatric 
non-adherence is needed.  
 
Figure 3. Correlates of Pediatric Chronic Illness Adherence. 
 
Critical analysis of relevant literature 
 
Because both hematopoietic stem cell transplant and solid organ 
transplant (SOT) patients are required to adhere to immunosuppressant therapy 
for an extended period of time, and due to the paucity of literature in HSCT, the 
solid organ literature was reviewed. The SOT research is based primarily on 
kidney and liver pediatric transplant patients, with little existing research on heart, 
lung and intestinal recipients  (Shellmer, Dabbs, Dew, 2011). Similarities 
between solid organ and HSCT are illustrated in Table 1. 
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Bone Marrow Transplant Solid Organ Transplant 
o Average LOS 2-8 weeks 
o Lifestyle and diet 
modifications 
o May not return to school for 6-
9 months 
o Must take 
immunosuppressant 
medication at least 9 months 
o Most frequently used IST = 
cyclosporine and tacrolimus 
o Average LOS 2-6 weeks 
o Lifestyle modifications 
o May not return to school 3-6 
months 
o Must take 
immunosuppressant 
medication for life 
o Most frequently used IST = 
cyclosporine and tacrolimus 
Table 1. Comparison of HSCT and Solid Organ Transplant. 
A total of 48 studies, 5 qualitative (Simons et al., 2009; Olaussun et al., 
2006; Bullington et al., 2007; Stilley et al., 2006; McAllister, Buckner, White-
Williams, 2006) and 43 quantitative studies (Appendix A) were reviewed. 
Included in the review were the 3 pediatric HSCT studies (Phipps, DeCuir-
Whalley, 1990; McGrady et al., 2014; Pai et al 2018). The five most commonly 
used measurement methods were: 1) self-report, 2) collateral report, 3) chart 
review, 4) direct methods (e.g., serum assay) or 5) a combination of one or more 
of the aforementioned methods. Only 20% of studies were prospective in nature. 
Studies examining children less than 10 years of age accounted for only 10% of 
the total. Adolescents were the most commonly studied population. Few studies 
combined both children and adolescents. Studies utilizing only one measure of 
adherence had higher rates of adherence than those using more than one 
method of measurement (Shellmer, 2011). Simons et al. (2009) demonstrated a 
combination of serum assay and self-report was predictive of poor health 
outcomes, but the same result was not found when the measures were used 
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separately. Additionally, studies using only chart review demonstrated rates of 
adherence two to three times higher than those using other indirect methods of 
measurement (Lurie et al., 2000; Phipps, DeCuir-Whalley 1990).  
Correlates. Few studies examined correlates or risk factors of non-
adherence. Of those that did, male gender, ethnic minority and older age were 
the most frequently cited socio-demographic factors associated with higher non-
adherence (Falkenstein et al., 2004; Feinstein, 2005; Takemoto et al., 2007; 
Shaw et al., 2003; Meyers, Weiland, Thomson, 1995; Ringewald, 2001; Fennell, 
2001; Aujoulat et al., 2011; Berquist et al., 2006). However, one study indicated 
females were more likely to be non-adherent (Korsch, Fine, Negrete, 1978). This 
can be attributed to side effects causing physical changes in adolescent girls 
(Griffin & Elkin, 2001) . A meta-analysis by Dew et al. (2009) reported non-
adherence twice as high in the adolescent population compared to younger 
children. Post-transplant characteristics associated with non-adherence included, 
longer time since transplant (McGrady 2014; ;Pai et al 2018), low family cohesion 
(Shemesh et al., 2004; Rapoff, 2010), and greater child and parental distress 
(Dew et al., 2009).  
Intervention research. The review identified only six intervention studies 
(Fennell, 1994; McGrady, 2014; Miloh, 2009; Shemesh, Annuziatio, Schenider et 
al., 2008; Beck, 1980; Pai et al 2018). Three studies evaluated educational 
interventions among liver and renal transplant patients (Beck,1980; Shemesh et 
al., 2008; Fennell, 1994). Fennell (1994) also used modeling and parent rewards 
for participation in medical care to enhance outcomes. These three studies 
provided varying results. Miloh et al. (2009) examined the use of text messaging 
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reminders to caregivers and/or patients. The results of this study demonstrated 
an increase in immunosuppressant levels and a subsequent decrease in 
rejection episodes. The two HSCT outpatient medication adherence studies 
previously described (McGrady et al., 2014; Pai et al 2018) were limited by small 
sample size (n= 6; n=50 respectively). One study only examined adolescents, 
making interpretation and relevance difficult. No multi-center trials were 
conducted, so generalizability of the interventions is problematic. Most of the 
intervention studies are educational, lack theoretical basis, have small sample 
sizes and include no long-term follow up.  
Measurement. A multidimensional approach to measurement of 
medication adherence using subjective (e.g., self-report, caregiver report, 
clinician assessment) and objective (e.g., serum assays, pill count, electronic 
monitoring, direct observation) methods have the most sensitivity and specificity 
for evaluating adherence (Dew et al 2009, Fredericks & Dore-Stites 2010, 
Quittner et al., 2008). However, no gold standard to assess medication 
adherence exists. Several studies have reported patients whose serum 
immunosuppressant levels were more than two standard deviations above the 
target range had a higher likelihood of identifying non-adherence and predicting 
late rejection than other measures (Shemesh et al., 2004, Bucuvalas et al., 2005, 
Stuber et al., 2008, Shemesh et al., 2008). Zelikovsky et al. (2008) reported that 
small variations in serum immunosuppressant’s lead to increased risk for graft 
loss in children. These findings led others to suggest standard deviation of serum 
immunosuppressant levels are the most reliable measure of medication 
adherence in pediatric solid organ transplant patients (Venkat,  Nick, Wang, 
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Bucuvlas, 2008;  Shemesh & Fine, 2010). These results have not been tested in 
a prospective longitudinal study or the hematopoietic stem cell transplant 
population.  
Limitations 
The three most common challenges in pediatric adherence research are 
1) lack of consistent adherence conceptualization, 2) majority of studies are 
cross-sectional and 3) high variability in assessment methodology (Steele & 
Grauer, 2003; Dew et al., 2009). Studies lack theory and vary widely in 
methodologies. Varying methodology and inconsistent representation of 
adherence significantly influences accuracy of data synthesis and design of 
intervention trials.  
Threats to Validity. Adherence research in the pediatric SOT populations 
is susceptible to a significant amount of bias. Selection bias exists due to lack of 
randomization and frequent use of cohorts and convenience samples. Individuals 
that decline to enroll could be at most risk for non-adherence and are not 
included in assessment. Attrition bias has been identified in SOT research, as 
subjects are frequently lost to follow up due to death or ceasing to participate. In 
intervention studies contamination risk can occur in the control group 
(Demonceau et al., 2013).  
Studies including pretest assessments are subject to testing threat 
(Fennell, 1994; Shemesh, Annuziatio, Shenider et al., 2008). Social threats of 
compensatory rivalry and resentful demoralization are possible given groups in 
solid organ transplant are frequently in clinic together. Mortality threats within this 
area of study are difficult to control and limit causal inference, due to the 
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likelihood that non-adherent patients are most expected to dropout. 
Immunosuppressant adherence studies to date lack strong evidence of causal 
inference because of the variation in assessment and lack of well controlled 
intervention trials. It would be difficult to make strong recommendations for an 
intervention to improve adherence based on the current literature within 
transplant, however, similar results across diseases utilizing text messaging have 
been reported and could be identified as the current recommended intervention 
for further study (Castano, 2012; Dowshen, 2012; Miloh, 2009). Until high-quality 
studies controlling for maturation effects with the capability of assessing those 
patients that chose not to enroll or withdraw from the study exist, it will be 
challenging to endorse a standard intervention for improving adherence.  
The majority of studies utilized convenience samples in settings that 
recruited subjects from local clinics. Use of this sampling method is a significant 
threat to interactions of the causal relationship with settings or the generalizability 
across settings (Shadish, 2002). Attrition was inconsistently reported and 
discussed among studies. Attrition within this area of study could significantly 
impact outcome, as those patients that withdraw from the study may also be the 
patients less likely to adhere.  
The validity of any scientific results depend on the manner in which the 
data is collected, the design and conduct of the study (Rosenberger , 2002). 
Validity is difficult to determine because of the self-report nature of measurement 
and limitations of objective measures of adherence  (Shemesh, 
Annuziatio,Shenider, et al. 2008). Within pediatric transplant medication 
adherence, there is a significant lack of intervention trials. In addition, adherence 
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has no “gold standard” of measurement; therefore a comparative analysis is 
difficult when multiple measures are used. A valid estimate of adherence is 
difficult to determine due to measurement limitations previously described, such 
as self-report (Shemesh, Annuziatio,Shenider, et al. 2008).  
 Methodology. Methodologies in the study of medication adherence widely 
vary (Di Matteo, 2004, Dobbels et al., 2005; Dew et al., 2009). Measurement and 
context variations cause significant disparities in estimates, correlates and 
outcomes of adherence (Di Matteo et al., 2002 ; Di Matteo, 2004). Fine et al. 
(2009) describe a challenge within the field as; wide variability in methods used 
to measure adherence and interpretation and accuracy of measurement 
problems. Another limitation of all studies was the lack of consistent follow up. 
Patients in the majority of studies had unequal follow-up time. The number and 
time points of patients lost to follow up varied across studies. 
 Measurement. A main research challenge in the adherence field is how to 
accurately measure adherence. Subjective reports have well-known limitations, 
specifically with respect to parent-child dyads. Objective data is difficult to obtain. 
For example, using pharmacokinetics can sometimes be inaccurate based on the 
absorption rate of the body (Shemesh et al., 2004; Shemesh & Fine, 2010). 
Medication Event Monitoring System (MEMS) programs are expensive and 
results can be falsified (De Civita, 2005). Within pediatrics, questions surrounding 
who to study arise: the child-patient, the parent-caregiver or both. In chronic 
disease, adherence has been shown to change over time as the burden of 
disease, symptom management and treatment fatigue increases (McGrady et al., 
2014; Coleman et al., 2012; Rapoff, 2010; Pai et al 2018). Therefore, the majority 
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of studies provide only a glimpse in time of adherence. Longitudinal studies of 
adherence in chronic illness would be more accurate and results could impact 
future intervention trials, but these are difficult to conduct due to attrition, funding, 
and patient numbers within pediatric transplant.  
Additionally, several studies found a composite measurement approach 
more accurate in detecting the highest rate of non-adherent patients (Schafer-
Keller 2008; Shemesh, et al., 2004). A study examining the combination of 
methods in renal transplant patients exhibited higher sensitivity (72.1%) when 
self-report was combined with serum assay method, rather than used in isolation 
(Schafer-Keller, 2008). Multiple methods of measurement are needed to provide 
convergent and discriminant validation (Hays, Di Matteo 1987). 
Gaps 
No “gold standard” of adherence measurement exists. Most tools are 
disease specific, and generalizability is difficult. No hematopoietic stem cell 
transplant specific adherence measures are available in pediatrics. Several 
measures for assessing immunosuppressant adherence have been used, 
however, few have been validated. The standard deviation method appears to be 
an effective measure for adherence in SOT; however, it lacks the ability to further 
evaluate details of the non-adherence. A combination of self-report and SD 
method is needed for a comprehensive assessment of adherence. Further 
development of standard deviation method including use in other populations and 
with other immunosuppressant medications is needed. Until a true “gold 
standard” is established a combination of direct and indirect measures is most 
appropriate in assessing adherence in pediatric transplantation. Further research 
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and collaboration is needed to better define a clinically significant level of 
adherence to aid in the development of more reliable and valid measures of non-
adherence.  
 Another considerable gap is related to the lack of studies in identified non-
adherent patients. In the meta-analysis conducted by Pai and McGrady (2014), 
only 4 of 23 studies included children and caregivers identified as non-adherent. 
The limitation of this approach is the small sample size in pediatrics, which leads 
to underpowered trials (Pai & McGrady 2014). True correlates of non-adherence 
cannot be identified until known non-adherent patients are studied. 
 Both solid organ transplant and hematopoietic stem cell transplant require 
multiple drug regimens over an extended period of time. Due to this, adherence 
is a dynamic process determined by multiple factors (Drotar, 2000). Evaluating 
the difficulty in adhering to a prolonged complex medication regimen over time is 
understudied (LaGreca & Bearman, 2003). A meta-analysis conducted by Pai 
and McGrady (2014) found only 9 studies with more than one follow up time. To 
date only three known studies examining adherence and the pediatric HSCT 
population have been published. A descriptive study of pediatric HSCT patients 
documenting prevalence and risk factors over the entire course of 
immunosuppressant therapy is crucial to a better understanding of HSCT 
adherence in general and over time. 
Purpose of the Study 
 
A better understanding of adherence in the pediatric stem cell transplant 
population is necessary to develop well-designed, effective intervention trials. A 
retrospective descriptive study was conducted in attempts to provide preliminary 
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data to describe prevalence and potential risk factors associated with non-
adherence. The findings will be used to establish a strong foundation for a 
program of research aimed at describing non-adherence, developing novel 
interventions, increasing adherence and ultimately improving outcomes in this 
vulnerable population. 
 The purpose of this study was to examine adherence to tacrolimus during 
the acute phase (first 100 days) post transplant in the outpatient setting. A 
retrospective chart review was conducted to describe patient characteristics, 
prevalence, and potential risk factors for tacrolimus adherence. The relationships 
between adherence and GVHD and readmissions were also examined.  In 
addition, further study of the standard deviation method was conducted.  
Specific Aims/Hypotheses 
 
AIM 1:  To describe adherence to tacrolimus in the pediatric outpatient HSCT 
setting. 
 
AIM 2:  To examine associations of adherence to tacrolimus with demographic 
characteristics and disease related factors in the pediatric outpatient HSCT 
setting. 
 
AIM 3: To compare the standard deviations of tacrolimus serum assay levels 
with documented adherence 
 
AIM 4: To describe the associations of adherence levels with GVHD and 
readmissions  
 
Definition of Terms 
 
Hematopoietic stem cell transplant (HSCT). Hematopoietic stem cell 
transplant (HSCT) is the transplantation of hematopoietic stem cells derived from 
bone marrow (i.e. ‘bone marrow transplant’ [BMT] or peripheral blood stem cells 
[PBSC]). HSCT became the common treatment for life threatening malignant 
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(e.g., acute leukemia, lymphoma) and non-malignant (e.g., aplastic anemia, 
sickle cell disease, thalassemia, immune deficiencies, genetic disorders) 
disorders in the mid1900s.  
HSCT is classified into two types; allogeneic and autologous. Allogeneic 
transplantation for children began in 1968 (Storb, 2004; Moore, Sakamoto, 
2005). ‘Allo’, meaning “other”, indicates the cells are derived from a related, 
unrelated or cord blood donor (Aschan, 2006 ; Korbling, Anderlini, 2001). The 
patient receives high-dose chemotherapy (preparative regimen) intended to 
eliminate neoplastic cells and ablate the healthy marrow to allow engraftment of 
the donor cells and complete immune reconstitution (Nuss, Barnes, Fisher, 
Olson, Skeens, 2011). Autologous transplantation is the process by which the 
patient receives his/her own cells. The procedure aims to salvage the bone 
marrow from high doses of chemotherapy used to treat the underlying disease 
(Wikle, Coyle, Shapiro, 1990).  
 Hematopoietic stem cell transplant is an aggressive medical treatment 
associated with high morbidity and mortality. Survival rates for HSCT vary from 
23 to 63% depending on the underlying diagnosis and type of transplant 
performed (Barrera, Pringle, Sumbler, & Saunders, 2000 ; Drew, Goodenough, 
Maurice, Foreman, & Willis, 2005 ; Pasquini & Wang, 2011). Primary disease, as 
well as complications that may occur during or immediately following the 
transplant affects these rates. The main risks are increased susceptibility to 
infection and transplant related complications such as graft vs. host disease 
(GVHD).  
Graft vs. Host Disease (GVHD). GVHD is a major complication occurring 
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in approximately 40-50% of all allogeneic transplants (Appelbaum, 2003). It is the 
effect of immunologic activation of donor lymphocytes attacking major and minor 
human leukocyte antigen (HLA) mismatches from the recipient (Ferrara et al., 
2009 ). Acute GVHD occurs within the first 100 days of transplantation. Any or all 
of the following manifests acute GVHD: skin rash, secretory diarrhea and 
hyperbilirubinemia. Acute GVHD is classified according to severity (see Table 2), 
and staging is indicative of prognosis (Glucksberg et al., 1974 ). Children that 
develop Grade 3 and 4 acute GVHD are at high risk for death. 
Due to the aforementioned risks and complications, recipients of HSCTs 
are required to adhere to complex, yet life-saving medication regimens. For 
example, immunosuppressive agents, most commonly calcineurin inhibitors 
(CNI) tacrolimus or cyclosporine, are crucial in prevention and treatment of 
GVHD. Morbidity and mortality due to GVHD can be decreased through 
prophylactic use of such immunosuppressant medications (Jacobsohn, 2008). 
Although these medications are costly and produce unpleasant side effects over 
extended periods of time, patient adherence to these medications is a central 
component to improved outcomes and increased quality of life.  
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Stage   Skin  Liver (bilirubin)  GI/Gut (stool output/day) 
0 No GVHD rash <2 mg/dL Child: <10 mL/kg/d; Adult: 
<500 mL/d 
1 Maculopapular rash 
<25% BSA 
2–3 mg/dL Adult: 500–999 mL/dd; Child: 
10–19.9 mL/kg/d; Persistent 
nausea, vomiting, or anorexia, 
with a positive upper GI biopsy 
2 Maculopapular rash 
25%–50% BSA 
3.1–6 
mg/dL 
Child: 20–30 mL/kg/d; Adult: 
1000–1500 mL/d 
3 Maculopapular rash 
>50% BSA 
6.1–15 
mg/dL 
Child: >30 mL/kg/d; Adult: 
>1500 mL/d 
4 Generalized 
erythroderma plus 
bullous formation and 
desquamation >5% BSA 
>15 mg/dL Severe abdominal pain with or 
without ileus, or grossly bloody 
stool (regardless of stool 
volume) 
Table 2. GVHD classification. Children's Oncology Group/Pediatric Blood and 
Marrow Transplant Consortium consensus, adapted from the modified 
Glucksberg system. 
BSA = body surface area; GI = gastrointestinal. 
 
Adherence. Haynes (1979) defined adherence as “the extent to which a 
person’s behavior coincides with medical or health advice” (pg. 1-2). Adherence 
has also been described as taking the correct amount of medication at a 
specified time (Bullington P., 2007). According to the WHO (2003) , adherence is 
defined as “the extent to which a person’s behavior – taking medication, following 
a diet, and/or executing a lifestyle change, corresponds with agreed 
recommendations from a health care provider.”  Prior to the WHO definition, the 
term compliance was used interchangeably with adherence. Compliance 
suggests patients follow physician orders without question; therefore adherence 
is now a more accepted term, suggesting collaboration in one’s own healthcare 
(Riekert & Drotar, 1999). Similar to HSCT, solid organ transplant (SOT) requires 
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prolonged immunosuppressant use to prevent graft rejection. In SOT literature, 
non-adherence is defined as “any deviation from the prescribed medication 
regimen sufficient to influence adversely the regimen’s intended effect” 
(Dobbels,, 2010). 
  Types of adherence. Non-adherent behavior has been categorized as 
volitional or inadvertent non-adherence (Bauman, 2000). Volitional non-
adherence occurs when the patient’s recommended treatment is in opposition 
with one’s own health beliefs. Complex regimens that do not provide assurance 
of cure or symptom relief commonly result in volitional non-adherence (Donovan 
& Blake, 1992; Johnson, 1994; Deaton 1985). Inadvertent non-adherence is 
unintentional by the patient or in the setting of pediatrics, the caregiver. 
Examples of inadvertent non-adherence include high medication costs, 
forgetfulness, a misunderstanding of the regimen or “good enough” adherence. 
Distinction between the types of non-adherence is important to the development 
of adherence-improving interventions (Riathavorn & Ettenger, 2005).   
 Operational definition. A crucial element in defining adherence is the 
lack of an established quantity of adherence that affects outcomes. Without 
knowledge of the specific amount of adherence that is significant, it is difficult to 
develop an instrument to measure adherence. Operationally, adherence has 
been defined multiple ways. Using serum assays to assess immunosuppressant 
drug levels, a standard deviation of greater than three is considered non-
adherent in the SOT population  (Shemesh et al., 2004). A commonly used 
operational definition is missed and late adherence scores. These are described 
as the number of doses prescribed by the provider minus the number of missed 
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doses, divided by number prescribed, times 100 to yield the percentage. Even 
utilizing this objective definition of non-adherence, no specific percentage has 
been identified as influencing clinical outcomes (Schafer-Keller, 2008; Simons, 
2009; Zelikovsky, 2008). To date, there has been no validated operational 
definition indicative of what level of non-adherence to immunosuppressive 
medications is significantly associated with poor medical outcomes (Dobbels, 
2005) in the pediatric stem cell transplant patient. 
Significance of the issue and need for study 
 
 Eighteen thousand bone marrow transplants are conducted annually in the 
United States, and almost 5,000 of these are in children and young adults with 
life-threatening diseases (cibmtr.org; Passweg 2014; Preussler, Denzen, Majhail, 
2012). These numbers continue to increase (Figure 4). Survey data confirms a 
continued and constant increase over the past 20 years in the annual numbers of 
transplant rates (number of HSCT/10 million inhabitants) for both allogeneic 
(related or unrelated donor) and autologous (self) HSCT. It is predicted that 
transplantation rates for allo-HSCT will continue to rise in the future as new 
indications for transplant emerge. (Passweg 2014; Majhail et al., 2010). A total 
projected increase in the number of transplants is estimated at two to three times 
the current number by 2020 (Moore et al., 2013; Majhail et al., 2013). 
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Figure 4. CIBMTR Summary Slide. Pasquini MC, Wang Z. Current use and 
outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 
2013. Available at: http://www.cibmtr.org 
A consistent limitation across adherence research is the lack of a reliable 
conceptual and operational definition. There is little descriptive adherence 
information known in pediatric HSCT. Further research to establish a reliable 
operational definition of medication adherence and identify the correlates and 
impact on health outcomes is needed. 
Due to the limited data in pediatric HSCT immunosuppressant medication 
adherence, it was necessary to establish a foundation of knowledge that would 
guide future research in this vulnerable population. Previous work in pediatric 
solid organ transplant indicated that gender, age, time since transplant, family 
cohesion and parental distress influenced overall adherence (Shellmer, Dabbs, 
Dew, 2011; Dew et al., 2009). To develop well-designed, effective intervention 
trials, an understanding of risk factors and affect on health outcomes was crucial. 
Data gained in this study of pediatric hematopoietic stem cell transplant patients 
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will add to the sparse knowledge currently available and establish a foundation 
for a program of research intended to further explore the phenomena, develop 
novel interventions, increase adherence and improve health outcomes in the 
vulnerable pediatric stem cell transplant population.  
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Chapter 2 
 
Tacrolimus Adherence in the Pediatric Stem Cell Transplant Population 
 
INTRODUCTION 
Hematopoietic stem cell transplant (HSCT) is the transplantation of 
hematopoietic stem cells derived from bone marrow (i.e. ‘bone marrow 
transplant’ [BMT] or peripheral blood stem cells). Hematopoietic stem cell 
transplant became the common treatment for life-threatening malignant diseases 
such as, leukemia and lymphoma, as well as non-malignant diseases including; 
aplastic anemia, sickle cell disease, thalassemia, immune deficiencies and 
genetic disorders in the mid1900s. Survival rates for hematopoietic stem cell 
transplant vary from 23 to 63% depending on the underlying diagnosis and type 
of transplant performed [1-3].   
 Hematopoietic stem cell transplant is an aggressive medical treatment 
associated with high morbidity and mortality. Underlying disease, as well as 
complications that may occur during or immediately following the transplant affect 
these rates. The main risks are increased susceptibility to infection and 
transplant-related complications such as graft vs. host disease (GVHD). The 
process can be physically and emotionally difficult for children and their parent 
caregivers. Recipients of hematopoietic stem cell transplants need to adhere to 
multifaceted outpatient regimens that require strict personal hygiene, 
environmental restrictions and complex medication regimens[4].  
Adherence 
According to the World Health Organization (2003) , adherence is defined 
as “the extent to which a person’s behavior – taking medication, following a diet, 
	 45	
and/or executing a lifestyle change, corresponds with agreed recommendations 
from a health care provider.”  Similar to HSCT, solid organ transplant (SOT) 
requires prolonged immunosuppressant use to prevent graft rejection. In SOT 
literature, non-adherence is defined as “any deviation from the prescribed 
medication regimen sufficient to influence adversely the regimen’s intended 
effect” [7]. 
Rates of adherence to recommended treatment have been reported at 
approximately 50% overall in pediatric patients [8]. These rates are typically 
lower in chronic disease when compared to acute illnesses [8, 9]. Across adult 
and pediatric studies, HSCT adherence rates range from 33% to 94.7% [10-14]. 
Adherence rates have been reported from 57 to 94.7% during the acute phase  
(first 100 days post-transplant) of pediatric SCT [13-15]. The most important 
determinants of non-adherence are consistently documented as complexity and 
duration of treatment regimens [16, 17]. Patients undergoing difficult pediatric 
hematopoietic stem cell transplants that require life-long medication are high risk 
for medication non-adherence. 
Adherence to immunosuppressant medications during the acute phase 
post-transplant is critical to prevent graft versus host disease (GVHD) and avoid 
graft failure.  GVHD is a major potential complication occurring in approximately 
40-50% of all allogeneic transplants [18, 19]. It is the effect of immunologic 
activation of donor lymphocytes attacking major and minor human leukocyte 
antigen (HLA) mismatches from the recipient [20]. Acute GVHD develops in the 
first 100 days post transplant. Pediatric patients that develop acute GVHD have a 
30 to 50% chance of survival. Morbidity and mortality due to GVHD can be 
	 46	
decreased through prophylactic use of immunosuppressant medications [21]. 
The most commonly used immunosuppressive agents are tacrolimus and 
cyclosporine. These medications are costly and produce unpleasant side effects 
over extended periods of time, however patient adherence to these medications 
is a central component to improved outcomes and increased quality of life. More 
complex medication regimens are associated with non-adherence; therefore 
pediatric HSCT recipients who must follow difficult post-transplant regimens are 
at high risk for poor adherence [22]. Lack of adherence to any of these regimens 
can be life threatening [11]. 
Immunosuppressant therapy is a life-long treatment used to prevent 
rejection in the pediatric solid organ transplant population. Non-adherence has 
been identified as common post transplant and has been found to be the most 
important reason for rejection [23, 24]. Blood levels of immunosuppressant 
medication, specifically tacrolimus, is an objective measure of adherence and 
has been shown to be directly related to whether patients took their 
medications[25].  
Few studies have described adherence in stem cell transplant. Of 5 
studies cited in a recent literature review[4], only two were pediatric [13, 14] and 
one combined adult and pediatric trial [12]. In 2018, Pai et al prospectively 
examined adherence in 50 pediatric HSCT patients during the acute phase post 
transplant. None of these studies specifically examined adherence to 
immunosuppressant therapy for children who have received a HSCT. Thus, the 
purpose of this study was to describe adherence to tacrolimus during the acute 
phase in outpatient pediatric stem cell transplant patients.  
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METHODS 
Participants and Setting 
This retrospective descriptive study included a sample of patients (N=57) 
who received an allogeneic hematopoietic stem cell transplant between 2009-
2016. Inclusion criteria included (a) patients from birth to 21 years of age (b) on 
tacrolimus-based immunosuppressant therapy, and (c) three or more weeks of 
evaluation as outpatients. Exclusion criteria included initial discharge after day 
100, disease progression, and early taper or change to other immunosuppressive 
medications. Interpretation of a single medication level can be unclear due to 
several factors including drug-drug interaction, diet, timing of medication, etc., 
therefore only patients with three or more weeks of outpatient evaluation were 
included.  
The study setting was a large Midwestern tertiary children’s hospital that 
performs approximately 40 transplants annually. Of those 40 transplants, 10 to 
15 are allogeneic transplants requiring immunosuppressant therapy. Unless 
otherwise indicated by a clinical trial, tacrolimus is the standard 
immunosuppressive agent.  
Procedures 
After hospital and university Institutional Review Board approvals, the 
Principal Investigator (PI) collected data via electronic medical record (EMR) 
reviews beginning with the first outpatient clinic visit post transplant. Data 
collection continued until the start of tacrolimus tapering, which begins between 3 
to 9 months post-transplant. The PI recorded data on all patients on the Medical 
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Record Data Form. To ensure data reliability, a practitioner with 15 years 
experience in HSCT acted as a secondary reviewer. This reviewer extracted data 
on approximately 20% of the subjects. Agreement between the two reviewers 
was 98%. As part of the standard of practice, patients were discharged at 
different days post-transplant due to varying diagnoses and illness stages. 
Therefore, patients had a varying number of follow-up visits for potential post-
discharge adherence to tacrolimus.  
Measures 
The Medical Record Data Form included factors that could potentially 
contribute to adherence. Data collected included gender, age in years at 
transplant, diagnosis, total number of medications (weekly), preparative regimen, 
and transplant characteristics. To examine associations between reported 
adherence and therapeutic levels, weekly graft vs. host disease scoring and 
readmissions during the first 100 days was collected. Adherence was measured 
using both subjective (indirect) and objective (direct) measures.  
Indirect Measure. The PI recorded patient non-adherence based on any 
subjective notes in the medical record from a physician or nurse indicating the 
patient was non-adherent to tacrolimus. We planned to collect the number of 
missed doses, however, providers did not document this information.  
Direct Measure. Tacrolimus was measured using the random whole blood 
concentration of 5-15 ng/mL (LC-tandem mass spectrometric assay) or 8-20 
ng/mL (measured by chemiluminescent immunoassay technique, Abbott 
diagnostics) [26-28]. The PI recorded weekly levels of tacrolimus from the EMR.  
In parallel with solid organ literature, non-adherence was defined objectively as 
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any tacrolimus level outside the therapeutic range of 5-14.99 ng/mL.  
Analysis 
The statistical package SPSS 24 © was used for statistical analysis. 
Descriptive statistics were used to describe demographics, transplant 
characteristics, indirect and direct adherence and variables associated with non-
adherence to tacrolimus therapy. Chi-Square tests of independence were used to 
test for differences between the characteristics of the groups of participants who 
maintained therapeutic levels and those who did not. An alpha of p < 0.05 was 
used for determining statistical significance. 
RESULTS 
Participants 
Eighty-seven patients received tacrolimus and were initially eligible for this 
study. Twenty patients were excluded due to discharge after day 100, death 
during transplant, disease progression, and early taper or change to other 
immunosuppressive medications. Ten patients were excluded because they had 
fewer than three outpatient tacrolimus levels. This resulted in a sample of 57 
patients. 
Summaries of the demographic characteristics of the 57 patients meeting 
the study inclusion criteria are shown in Table 1. The median age was 7.6 years 
(range 1 month to 21 years), majority white (77%) with a malignant diagnosis 
(61%). Transplant characteristics are shown in Table 2.  The majority of patients 
(67%) underwent a matched unrelated donor transplant with bone marrow (72%) 
as the stem cell source.  The most common preparative regimen was 
chemotherapy and anti-thymocyte globulin (ATG) (42.1%).   
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Adherence to Tacrolimus Therapy 
An evaluation of EMR records documented 357 clinic visits for the 57 
patients (range = 4 - 23 per patient). Subjective (indirect) adherence was not 
recorded in 51% of the visits. In 175 visits that documented adherence, there 
were six episodes of non-adherence in three patients. An overall subjective 
adherence rate was 95%. Due to the small number (n=3) of reported non-
adherence, subjective non-adherence did not statistically correlate with non-
therapeutic levels, however 50% of the documented non-adherent visits had non-
therapeutic levels. Serum assay levels were non-therapeutic in 16.7% of patients 
with documented subjective adherence. No indirect (subjective) non-adherence 
was documented after week six.   
Summaries of the weekly tacrolimus levels for the 57 patients are shown 
in Table 3.  More than half of the patients (n=34, 58%) demonstrated non-
therapeutic levels (<5 or > 15) for at least one of their weekly visits. Within the 
first 3 weeks post-discharge (time frame during which most of the same had 
weekly data, median values ranged from 8.7 to 9.4 and the percent of patients in 
the non-therapeutic range was between 16% and 24% (see Table 4). The 
tacrolimus levels for over half of the patients (53%) were non-therapeutic > 20% 
of the time.  Approximately 34% of the patients were non-therapeutic > 40% of 
the time.  
Tacrolimus Adherence and Associated Demographic Variables  
 Table 4 provides summaries and comparisons of the characteristics of the 
sub-therapeutic and therapeutic groups of patients. As shown in Figure 1, those 
who had at least one non-therapeutic levels were in the post-discharge period for 
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a longer number of weeks than those with all therapeutic levels (mean=7.6 
weeks, SD=2.8 vs. mean=6.0, SD=2.0, p=.002) (Figure 1). The majority of 
patients in both the adherent and non-adherent groups were male and with 
malignant diagnosis (difference between groups p < 0.05). Although not 
statistically significant, 2.5 times more females were noted in the non-therapeutic 
group. Children ages one to five years of age were most commonly outside the 
therapeutic range (36.3%). Contrarily school age children (39.1%) and 
adolescents (39.1%) were of the majority in the therapeutic group.  
Tacrolimus Adherence and Outcomes 
We also examined potential association of adherence with graft versus 
host disease and readmissions. The overall post-discharge GVHD rate for 
participants was 38.6%. No statistically significant difference was observed 
between the therapeutic and non-therapeutic groups for GVHD. The non-
therapeutic group had a GVHD rate of 41.2% compared to 34.8% in the 
therapeutic group (p=0.627). The readmission rate was approximately 30% for 
both groups (p=0.934).   
Discussion 
 These are the first known results reporting adherence to 
immunosuppressive agents in the acute post-transplant phase in pediatric 
hematopoietic stem cell transplant patients. Using previously reported solid organ 
literature that suggests levels outside of the therapeutic range correlate with 
adherence [24, 25, 29-33] our study found an overall adherence rate of 59.6% 
using the direct serum assay method. Across studies of adherence to general 
medications in the post-transplant population, adherence rates are reported from 
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33% to 95% using various measures [4].   
In our study, fewer than half of the provider notes subjectively documented 
adherence. Similar to Hoodin et al (1993) that reported an indirect adherence 
rate of approximately 95%, our study reported 96% adherence in those patients 
where subjective adherence was recorded. It is, however, well known that 
adherence goes under reported as noted in this study in which 51% of clinic visit 
records did not document adherence or non-adherence. Providers and parents 
overestimate medication adherence [4]. Consistent with the findings of our study, 
studies using only chart reviews have demonstrated rates of adherence two to 
three times higher than those using other indirect methods of measurement [34] 
[14].  
Although small numbers, in our study of those that reported episodes of 
non-adherence, 50% had non-therapeutic levels. This compared to the group 
that reported adherence, only 16.5% had non-therapeutic levels. Hoodin et al. 
(1993) has suggested fabricated self-report rates based on finding adherence 
rates of 50% when indirect measures of adherence were correlated with pill 
counts. These reasons support recommendations for more direct measures of 
adherence monitoring. 
While not statistically significant in our study, more than two times the 
number of females were noted in the non-therapeutic group. This is contrary to 
the majority of studies that report males have higher non-adherent rates [31, 35]. 
Also of interest in our study, children 1 to 5 years of age were most frequently in 
the non-therapeutic group. These results are similar to the inpatient retrospective 
study that reported lower subjective adherence in children ages 2 to 12 [14]. 
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However, other studies have suggested that non-adherence is highest in the 
adolescent age group [31, 36-44].  The younger age group has been 
understudied in adherence literature. Previous work in pediatric solid organ 
transplant indicates that gender, age, time since transplant, family cohesion and 
parental distress influence overall adherence [31, 45].  Further studies evaluating 
family factors, as well as facilitators and barriers to adherence in the pediatric 
HSCT population is needed.  
Our study found no correlation between GVHD rates and readmissions 
between groups. We did not specifically evaluate infections, however, Pai et al 
(2018) examined 50 outpatients and found a statistically significant correlation 
between adherence to higher infection rates (p<.005); an average adherence 
rate of 63% during the acute phase post-transplant was reported. This study also 
did not focus on immunosuppressant medications. Interestingly, the adherence 
rate decreased to 57% at 6 months post transplant [15].  
Three pediatric adherence studies in the HSCT population have been 
reported in the literature [13-15]. None of these studies examined solely 
immunosuppressant medications. There was considerable variability in 
adherence measurement methods among the studies. One study (n= 54) 
retrospectively examined adherence in the inpatient setting [14]. Nursing 
documentation and nursing diagnosis were used to assess adherence. The 
overall adherence rate was reported at 50%, but did not specifically examine 
immunosuppressive medications.  
A more recent study examined adherence to outpatient medications in the 
adolescent population post-transplant [13]. This study of six patients found 
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patients took an average of 73% of their medications. At least one dose was 
missed approximately 3 days a week. Additionally, adherence worsened over 
time. Although small numbers, the results of this study suggest adherence in the 
pediatric HSCT population is poor. 
With so few published studies, research in this area is scarce. There are 
still no established definitions of adherence, standardized measurement, 
established rates that affect outcomes or effective interventions to treat and 
prevent this problem. Facilitators and barriers remain unknown and the patient 
and family perspective has yet to be explored.  
Limitations 
The authors acknowledge several limitations to the study. The study was a 
small retrospective descriptive study conducted at one site. The acute phase of 
transplant had a variable length of time and therefore a different number of 
opportunities for adherence due to longer inpatient stays, readmissions and early 
weaning was noted between groups.  
There is also concern for the reliability of self-report adherence. Using one 
method of adherence can lead to threats of bias; therefore, the direct measure of 
tacrolimus assays was also included. We acknowledge that many factors affect 
therapeutic levels of immunosuppression. Changes in blood levels can happen 
as a result of other factors including absorption problems, diet and drug-drug 
interactions [46]. Despite these factors, solid organ literature examining drug 
levels and subjective adherence found a direct correlation between non-
therapeutic levels, adherence and graft rejection [25, 46, 47].  
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CONCLUSION 
 
This is the first known study to examine adherence to tacrolimus in the 
acute phase post-transplant. Although our indirect adherence rate of 96% was 
high, our overall adherence rate of 58% using direct measure is similar to what 
has previously been reported. Perhaps more concerning is over half of the 
patients (53%) were non-therapeutic > 20% of the time and 34.4% of the patients 
were non-therapeutic > 40% of the time.  
 There is a significant need for adherence research in the pediatric stem 
cell transplant population. Further studies are needed to determine facilitators 
and barriers, best measurement methods, correlations to outcomes, as well as 
interventions to improve adherence. The potential severe consequences of poor 
adherence, such as GVHD, infection and mortality require the transplant 
community to move adherence research to the forefront. Good adherence is 
fundamental to safe, cost-efficient transplant with optimal long-term outcomes. 
Research to improve adherence is crucial.   
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Table 1. Sample Characteristics (n=57) 
 
Characteristic M SD 
Age at transplant 8.51 (1m – 20y) 5.94 
Characteristic                                        n (%) 
Gender 
  Male 
  Female 
 
   
36 (63.2) 
21 (36.8) 
Race 
 White 
 Black 
 Asian/Pacific Islander 
 Arabic 
 Other 
 
                44 (77.2) 
  9 (15.8) 
1 (1.8) 
 2 (3.5) 
1 (1.8) 
Diagnosis 
Leukemia 
Lymphoma 
Immunodeficiency 
Metabolic Disorder 
Hemoglobinopathies 
Bone Marrow Failure 
 
 
34 (59.6) 
1 (1.8) 
3 (5.3) 
5 (8.8) 
10 (17.5) 
4 (7) 
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Table 2. Transplant Characteristics (n=57) 
Characteristic n(%) 
Transplant Type 
Matched Sibling Donor 
 Matched Related Donor 
Matched Unrelated Donor 
   
18 (31.6) 
1 (1.8) 
38 (66.7) 
Stem Cell Source 
Bone Marrow 
Peripheral Blood Stem Cell 
Umbilical Cord Blood 
 
41 (71.9) 
7 (12.3) 
9 (15.8) 
Preparative Regimen 
 Anti-Thymocyte Globulin 
 Total Body Irradiation 
 Campath 
 Chemotherapy Alone 
 
24 (42.1) 
21(36.8) 
7 (12.3) 
5 (8.8) 
GVHD Prophylaxis 
Tacrolimus/Methotrexate 
Tacrolimus/Mycophenolate Mofetil 
Tacrolimus Only 
 
 
36 (63.2) 
16 (28.1) 
5 (8.8) 
  
 
 
 
 
 
 
 
 
 
 
	 65	
Table 3. Weekly description of patients and therapeutic ranges 
 
Week Post 
Discharge 
N < 5.0 5.0-14.9 >= 15.0 Median Min, Max 
1 55 6 42 7 8.7 3.2, 21.8 
2 55 5 46 4 8.9         2.0, 25.7 
3 53 5 43 4 9.4 2.4, 13.3 
4 33 1 29 3 8.1 3.3,15.9 
5 46 6 38 2 8.9 3.1, 19.1 
6 32 1 28 3 8.7 4.8, 20.4 
7 30 3 26 1 8.9         4.0, 15.0 
8 20 1 17 2 10.5 3.4, 18.3 
9 12 1 8 3 9.3 3.3, 16.6 
10 3 0 3 0 10.8 6.6, 11.9 
11 3 1 2 0 9.3 3.1, 11.9 
  
Note: Median and min, max are used to summarize the continuous values 
due to small number of observations per participant range (1-7 weeks). 
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 Table 4. Comparison of Non-Therapeutic and Therapeutic Groups (n=57) 
 
 
 
 
 
Figure 1.  Number of weeks of observation between therapeutic and non-
therapeutic groups 
 
 
 
Characteristic Non-therapeutic 
Total n= 34 
n(%) 
Therapeutic 
Total n= 23 
n (%) 
p-value 
Gender 
    Male 
    Female 
 
19 (55.9) 
15 (44.1) 
 
17 (73.9) 
6 (26.1) 
0.166 
 
Age 
    <1y 
    1-5y 
    6-10y 
    11-20y 
 
2 (5.8) 
12 (35.3) 
9 (26.5) 
11 (32.4) 
 
4 (17.4) 
4 (17.4) 
7 (30.4) 
8 (34.8) 
0.335 
 
Disease 
Leukemia 
Lymphoma 
Hemoglobinopathy 
Immunodeficiency 
Metabolic Disorder 
 
20 (60.6) 
1 (3) 
8 (21.2) 
2 (6) 
3 (9) 
 
 
14 (65.2) 
0 
2 (8.7) 
5 (21.7) 
2 (4.3) 
0.136 
 
GVHD 14 (41.2) 8 (34.8) 0.627 
Readmissions 10 (29.4) 7 (30.4) 0.934 
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Chapter 3 
 
The Medication Level Variability Index (MLVI) is Predictive of Graft vs. Host 
Disease in Pediatric Hematopoietic Stem Cell Transplant Patients 
INTRODUCTION 
Graft-versus-host-disease (GVHD) is a major potential complication 
occurring in approximately 35 to 50% of allogeneic transplants [1].  It is the effect 
of immunologic activation of donor lymphocytes attacking major and minor 
human leukocyte antigen (HLA) mismatches from the recipient [2]. Acute GVHD 
develops in the first 100 days post transplant.  Pediatric patients that develop 
acute GVHD have a 30 to 50% chance of survival. Morbidity and mortality due to 
GVHD can be decreased through prophylactic use of immunosuppressant 
medication [3].  The most commonly used immunosuppressive agents are 
tacrolimus and cyclosporine.  
Routinely measured tacrolimus blood levels are standard of care for 
children receiving hematopoietic stem cell transplants (HSCT) and solid organ 
transplants (SOT).  One sub-therapeutic or elevated level is difficult to interpret 
due to many factors that may influence the result. Due to this, in solid organ 
transplant, the degree of fluctuation between levels is used.  This is done by 
calculating the standard deviation (SD) of consecutive tacrolimus assays and 
becomes the Medication Level Variability Index (MLVI) biomarker.  The higher 
the MLVI, the greater the degree of fluctuation [4].  In children undergoing solid 
organ transplant, the MLVI is significantly associated with acute rejection [5-8]. 
In solid organ transplant recipients, immunosuppressant therapy is a life-
long treatment used to prevent rejection. Non-adherence is common post 
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transplant and has been found to be the most important reason for rejection [5, 
9]. Blood levels of immunosuppressant medication, specifically tacrolimus, is an 
objective measure of adherence and has been shown to be directly related to 
whether patients took their medications [7]. Few studies exist in pediatric 
hematopoietic stem cell transplant that examine adherence.  To our knowledge, 
no specific studies have examined adherence to immunosuppressant 
medications and the association with adverse outcomes, such as GHVD.   
Immunosuppressant medications are costly and produce unpleasant side 
effects over extended periods of time, factors that are known to influence 
adherence. However, patient adherence to these medications is a central 
component to improved outcomes and increased quality of life.  Adherence to 
immunosuppressant medications during the acute phase post-transplant is 
critical to prevent GVHD and avoid graft failure.  
To date, no established “gold standard” to measure pediatric 
immunosuppressant adherence exists. Subjective self-report measures are 
commonly used in general adherence research [10]. Solid organ literature uses 
combination of measures to increase diagnostic accuracy [11, 12]. Shemesh et 
al. (2004) describe the standard deviation method of tacrolimus as an indicator of 
adherence and a prediction of graft failure. Preliminary work suggests standard 
deviations of tacrolimus assays may also have clinical utility in the pediatric 
HSCT population. However, the association and potential predictability with 
adverse outcomes has not been established.  The purpose of this study is to 
examine the association of the MLVI biomarker with GVHD, and examine its 
potential predictive value in the pediatric hematopoietic stem cell transplant 
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patient during the acute phase post transplant.  
METHODS 
Participants and Setting 
The sample from this retrospective descriptive study represented children 
(N=64) who received allogeneic bone marrow transplants at a large Midwestern 
tertiary children’s hospital from 2008 to 2016.  Eighty-seven patients received 
tacrolimus and were initially considered for this study.  A total of 64 patients met 
all criteria for analysis. Inclusion and exclusion criteria were the following: 
Inclusion criteria:  
1. Age birth to 21 years of age 
2. Allogeneic transplant 
3. Tacrolimus based immunosuppressant therapy  
Exclusion criteria:  
1. Discharge after day 100  
2. Death prior to discharge  
3. Change to alternate immunosuppression  
4. Returned to referring hospital, no follow-up  
5. Less than 3 outpatient tacrolimus levels  
Procedures 
The principal investigator (PI) collected data via the electronic medical 
record (EMR), after hospital and university Institutional Review Board approval. 
Data collection began with the first post transplant outpatient clinic visit.  At the 
start of tacrolimus tapering, usually between 3 to 9 months post-transplant, data 
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collection ended.  As per standard practice, patients are discharged at varying 
days post-transplant due to engraftment, diagnosis and transplant complications; 
therefore each patient had a varying number of tacrolimus levels recorded.  To 
ensure data reliability, an advanced practice nurse with 15 years experience in 
HSCT acted as a second data collector.  This practitioner independently 
extracted data on approximately 20% of the subjects.  Percent agreement 
between the two reviewers was 98%.  
Measures 
The Medical Record Data Form included patient gender, age at transplant, 
diagnosis, total number of medications (weekly), preparative regimen, type of 
donor and stem cell source.  To examine associations of MLVI with outcomes, 
the PI collected weekly graft vs. host disease scoring and readmissions during 
the first 100 days. 
Tacrolimus was measured using the random whole blood concentration of 
5-15 ng/mL (LC-tandem mass spectrometric assay) or 8-20 ng/mL (measured by 
chemiluminescent immunoassay technique, Abbott diagnostics)[13] [14] [3].  The 
PI recorded weekly and bi-weekly levels of tacrolimus from the EMR.  
The Medication Level Variability Index (MLVI) 
Tacrolimus trough levels are routinely obtained, weekly or bi-weekly 
during the acute phase post-transplant, as standard of care.  The MLVI was 
calculated as the standard deviation of a set of at least three tacrolimus trough 
blood levels for each participant, as described elsewhere [15] 
Primary outcome measure Graft vs. Host Disease (GVHD) and Readmissions 
The clinic provider assessed and documented a GVHD score at each visit. 
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The PI retrospectively recorded from the EMR overall presence, type and 
maximum grade of GVHD. The PI reviewed all medical records for readmissions 
between clinic visits.   Readmission occurrence and date were recorded.  The 
reason for readmission was not collected in this study. 
Analysis 
SPSS version 24 © was used for statistical analysis. Frequency 
distributions were used to summarize the nominal and ordinal data collected in 
this study; median and inter-quartile range [IQR] were used to summarize most 
of the continuous data due to skewness of those distributions. Mean and 
standard deviation (SD) summarized normally distributed continuous data. Mann-
Whitney tests were used to compare the MLVI values for the readmission and 
GVHD groups of patients. Logistic regressions were used to generate the extent 
to which MLVI increased or decreased the likelihood of readmission or GVHD. 
Finally, the area under receiver operating characteristic curve (AUC ROC) was 
used to evaluate the possible sensitivity and specificity of the MLVI for predicting 
readmission or GVHD in subsequent studies. Statistical significance was 
determined using an alpha of 0.05. 
RESULTS 
Participants 
Patient demographic characteristics of the 64 participants are shown in 
Table 1. The median age was 7 years (range 1 month to 21 years).  The majority 
of children were white (n = 49; 76.6%) with a malignant diagnosis (n = 41; 64%). 
Transplant characteristics are shown in Table 2.  The majority of patients (n = 43; 
67.2%) underwent a matched unrelated donor transplant with bone marrow (n = 
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46; 71.9%) as the stem cell source.  The most common preparative regimens 
included chemotherapy plus anti-thymocyte globulin (ATG) (n=24; 37.5%) or 
chemotherapy plus total body irradiation (TBI) (n=22; 34.4%).  
The study evaluated a total of 406 tacrolimus levels in 64 patients over a 
varying number of weeks per participant (median=8, min=3, max=11).  
Summaries of the weekly tacrolimus levels are shown in Table 3. A total of 72 
episodes of non-therapeutic levels occurred during the acute phase.  Of those, 
40 (56%) were < 5, while 32 (44%) were >15.  
MLVI 
The median MLVI value for all 64 patients was 2.68 with 50% of the 
patients having values between 1.84 and 4.20 (see Table 4). Seven patients 
were excluded from the readmission and GVHD analyses, as no EMR record for 
determination was available. 
GVHD. Approximately 39% (n=25 of 64) of the participants in the study 
had  GVHD post-discharge. The MLVI values for the two groups are summarized 
in Table 4. Those with GVHD had a statistically significantly higher MLVI than 
those that did not (median=3.1, IQR=2.5-4.7 vs. 2.3, IQR=1.6-3.4 respectively, p 
=. 024). Of those patients with GVHD (n=25), 80% (n=20) had an MLVI greater 
than 2 and 60% (n=15) had an MLVI greater than 3. Using a criterion of MLVI > 
3, there was a statistically significant increased likelihood of GVHD (OR=3.82, 
95% C.I.=1.32-11.04, p = 0.013). Using the continuous value of MLVI, the 
association was not statistically significant (OR=1.34, 95% CI=0.96 – 1.85, p = 
0.086). A criterion of >2 SD also was not statistically significant yet the effect size 
was only slightly smaller than that observed for 3 SD (OR=3.09, 95% C.I.= 0.96-
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9.93).  The association of MLVI with the grade of GVHD could not be assessed 
due to the limited variability in GVHD grade in this sample. Eighty-seven percent 
of patients had a GVHD grade 1 or less. Area under the curve (AUC) calculation 
for the sensitivity and specificity of using the MLVI for GVHD is shown in Figure 
1. The AUC of 0.67 was statistically significant (95% C.I. 0.53-0.81, p=. 024). 
This is approaching the 0.7 general criterion necessary for “potentially useful 
laboratory test”[16]. Using this approach and evaluating the 
sensitivities/specificities, an optimal value appears to be between 2 and 3 SD. 
Readmission. Of the 57 patients evaluable, the readmission rate was 30% 
(n=17). Summaries of the MLVI values for those two groups are also shown in 
Table 4 and were not statistically significantly different (p=.216). Of those patients 
readmitted to the hospital (n=17), the majority (70.6%, n= 12) had an MVLI 
greater than 2 and over half (52.9%, n=9) were greater than 3. None of the 
logistic regressions using MLVI demonstrated a statistically significant increased 
likelihood of readmission (continuous: OR=1.19, 95% C.I.= 0.85-1.68, p=. 317; > 
2 SD: OR=1.60, 95% C.I.= 0.47-5.42, p=. 450; > 3 SD: OR=2.34, 95% C.I.= 0.73-
7.45, p=.151). Figure 2 displays the area under the curve (AUC) calculation for 
the sensitivity and specificity of using the MLVI for readmission. As would be 
expected given the findings from the other approaches, the AUC approach was 
also not statistically significant with a value of 0.60 (95% C.I.= 0.45-0.76, 
p=.216). 
DISCUSSION 
 This retrospective chart review study of 64 pediatric hematopoietic stem 
cell transplant patients tested the predictability and association of the MLVI, a 
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biomarker obtained by calculating the standard deviation of a series of tacrolimus 
levels, with two common post-transplant adverse outcomes; GVHD and 
readmissions. The MLVI represents the degree of fluctuation between individual 
medication blood levels. A higher MLVI is associated with and predictive of graft 
rejection in other transplant populations [4]. 
 Our study found the MLVI to be a potential predictor of GVHD in HSCT 
patients.  However, there was no such association between MLVI and 
readmissions. We did not examine other outcomes such as death or infection 
rates.  In previous studies, there is strong evidence to suggest MLVI is strongly 
correlated with adherence.  These studies correlated the MLVI with electronic 
monitoring of adherence [17] as well as  behavioral interventions to improve 
adherence [18, 19].  Although our study did not address the reason for the 
variability in the index, we believe, consistent with literature in other transplant 
populations [4, 5, 7, 20], adherence could be a cause.  
 Our overall GVHD rate was 39.1%.  The clinical utility of a “cut-off” seems 
reasonable as the majority of patients (72%) that did not develop GVHD 
maintained a MLVI of < 3.  Similarly of those patients readmitted, 71% had an 
MLVI >2, although not statistically significant. Unlike a previous study [20], that 
reported younger children were more stable with lower MLVIs, our study 
demonstrated children age 1 to 5, as well as adolescents, were more likely to 
have MLVIs with SD > 3.  
Calculating the MLVI is more advantageous than looking at one blood 
level. Metabolic, absorption issues and drug-drug interactions that influence 
individual blood levels, do not effect the MLVI [20]. These factors can lead to low 
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levels, but not necessarily variable levels.  The Index has identified non-adherent 
patients, not patients with metabolic or absorption issues [4]. The MLVI is a 
reproducible marker of the adequacy of immunosuppression in other transplant 
populations [4, 21].  
MLVI and Adherence 
Very limited data in hematopoietic stem cell transplant exists regarding 
adherence.   Three pediatric studies examining adherence to medications post 
HSCT, report an adherence rate ranging from 50% to 73% [22-24]. Our initial 
study attempted to retrospectively examine subjective adherence to tacrolimus 
and found in over 50% of the patients adherence was not recorded at the clinic 
visit and when it was, adherence went under reported (Skeens et al, under 
review).  
In other transplant populations, MLVI is directly correlated with non-
adherence, although not tested in our population. Advantages of the MLVI in 
clinical practice includes that it does not rely on subjective reporting, imposes no 
additional patient burden and in adherence research, mitigates selection bias. 
This, combined with the knowledge that indirect measures are not optimal ways 
to assess adherence, calls for further research to correlate the utility of the MLVI 
biomarker and adherence in the pediatric stem cell transplant patient. The ability 
to recognize these patients early on and develop interventions targeting 
adherence barriers is essential to the overall outcomes of transplant patients.  
Limitations 
This is a single institution, retrospective chart review of a small number of 
pediatric stem cell transplant patients.  A larger cohort of patients is needed to 
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fully determine the validity of the cut-off value of s.d > 3 and further evaluate the 
ROC.  The lack of adherence data makes it difficult to determine if this is a 
clinically valid direct measure of adherence for this specific population, however it 
has been shown to correlate with adherence in other transplant populations.  
Clinical Implications 
Despite the limitations, our study has important clinical implications. The 
MLVI is easy to calculate and inexpensive to use.  In practice, it could be 
continuously recalculated every time a blood level is obtained. This index is 
capable of identifying at-risk patients who could otherwise be missed and lead to 
early identification of patients that develop GVHD.   
The consequence of GVHD to a stem cell transplant patient is high. 
Children that develop GVHD are subjected to additional immunosuppression, 
ultimately leading to higher rates of morbidity and mortality.  Non-adherence to 
tacrolimus could lead to sub-therapeutic levels, making it one of the most 
potentially important causes in the development of GVHD.  Non-adherence is 
one of a very few modifiable risk factors that is not routinely addressed or 
assessed in this population.  By addressing this risk factor, clinicians have an 
opportunity to affect post-transplant outcomes.  Using the MLVI biomarker to help 
predict those children at risk for GVHD and potential non-adherence could be a 
good first step.   
Conclusion 
This is the first known study to report the use of the MLVI in hematopoietic 
stem cell transplant patients.  The MLVI is associated with a main adverse 
outcome related to hematopoietic stem cell transplant, GVHD.  These results are 
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encouraging of a new potential biomarker to evaluate tacrolimus serum assay 
levels and identify patients at risk for developing GVHD.  Future research to 
further validate this measure and the relationship to adherence is necessary to 
improve outcomes for children undergoing hematopoietic stem cell transplant.  
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Table 1. Sample Characteristics 
 
Characteristic M SD 
A  Age at transplant 8.2 (1m – 20.3y) 6.08 
C Characteristic n (%) 
  gGender  
     Male 
     Female 
 
   
40 (62.5) 
24 (37.5) 
R Race 
     White 
     Black 
     Asian/Pacific Islander 
     Arabic 
     Other  
 
49 (76.6) 
10 (15.6) 
1 (1.6) 
2 (3.1) 
2 (3.1) 
Di Diagnosis  
     Leukemia 
     Lymphoma 
     Immunodeficiency  
     Metabolic Disorder 
     Hemoglobinopathies 
     Bone Marrow Failure 
 
 
39 (60.9) 
2 (3.1) 
3 (4.7) 
5 (7.8) 
10 (15.6) 
4 (7.8) 
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Table 2. Transplant Characteristics 
 
     Characteristic n(%) 
Tr  Transplant Type 
     Matched Sibling Donor 
     Matched Related Donor 
     Matched Unrelated Donor 
   
19 (29.7) 
2 (3.1)       
43 (67.2)    
     Stem Cell Source 
     Bone Marrow 
     Peripheral Blood Stem Cell 
     Umbilical Cord Blood 
 
46 (71.9) 
97 (14.1) 
9 (14.1)    
     Preparative Regimen  
     Anti-Thymocyte Globulin 
     Total Body Irridation 
     Campath 
     Chemotherapy Alone 
 
24 (37.5)) 
22 (34.4) 
7 (10.9) 
5 (7.8) 
     GVHD Prophylaxis 
     Tacrolimus/Methotrexate            
     Tacrolimus/Mycophenolate Mofetil    
     Tacrolimus Only 
 
 
43 (67.2) 
16 (25) 
5 (7.8) 
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Table 3. Weekly Tacrolimus levels 
 
 
 
 
 
 
 
 
Table 4. MLVI and Outcomes 
 
Characteristic GVHD 
n=25   
NO GVHD 
n=39 
Readmit 
n= 40 
No Readmit  
        n= 17 
     
Median (IQR) 3.09 
(2.58, 4.67) 
 
2.29 
(1.62, 3.37) 
 
3.04 
(1.72, 4.13) 
2.47 
(1.90, 4.74) 
Range 0.96-6.42 
 
0.10-13.27 0.96-13.27 0.10-7.74 
     
 
 
 
 
 
 
 
 
 
 
 
 
Week 
Post 
Discharge 
N <5 5-
14.99 
>= 15 Median Min, Max IQR 
1 62 10 45 7 8.6 0.0, 21.8 6.0 - 11.5 
2 62 6 51 5 8.9 2.0, 25.7 6.1 – 12.9 
3 59 6 49 4 9.4 0.0, 13.3 7.0 – 13.3 
4 40 2 35 3 8.1 3.3,15.9 7.0 – 10.0 
5 52 7 43 2 8.9 3.1, 19.1 6.5 – 10.9 
6 38 1 34 3 8.8 4.8, 20.4 7.0 – 10.6 
7 35 3 31 1 8.4 4.0, 15.0 6.7 – 11.0 
8 25 1 22 2 10.0 3.4, 18.3 8.1 – 12.8 
9 17 1 13 3 8.0 3.3, 16.6 6.5 – 11.1 
10 8 1 7 0 8.5 4.0, 12.0 6.9 – 11.6 
11 8 2 4 2 9.2 3.1, 15.0 4.5 – 14.2 
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Figure 1. GVHD ROC Curve 
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Figure 2. Readmission ROC Curve 
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Chapter 4 
 
             Summary of Findings, Implications and Directions for Future 
Research 
 
 
The purpose of this study was to examine outpatient adherence to 
tacrolimus during the acute phase (first100 days) post-HSCT in children. A 
retrospective chart review was conducted in an attempt to describe patient 
characteristics, prevalence, and potential risk factors associated with tacrolimus 
adherence. The relationships between adherence and adverse outcomes, GVHD 
and readmissions were also examined. In addition, study of the standard 
deviation method to obtain a novel biomarker the Medication Level Variability 
Index was completed. This chapter presents a brief summary of the study, 
implications and directions for future research. The limitations to this study will 
also be presented. 
Aim 1: Description of adherence 
 
The first aim of the study was to describe adherence to tacrolimus in the 
pediatric outpatient HSCT setting. Due to the retrospective nature of this study, 
indirect adherence data was difficult to collect. Subjective adherence was 
routinely recorded in less than half of the patients. Only three patients, with a 
total of six occurrences were identified as non-adherent as documented in 
provider clinic notes. Contrarily, 58% of patients had tacrolimus levels outside the 
therapeutic window. All the patients identified as non-adherent had non-
therapeutic levels at some point during the course of monitoring. The lack of 
consistent assessment and documentation is a clear gap in practice and an area 
for further research to establish the true magnitude of the problem. 
	 88	
Aim 2: Adherence factors 
 The second aim was to examine the associations of tacrolimus adherence 
with demographic and disease related factors. This aim was not possible due to 
the small number of reported non-adherent episodes. However, our findings were 
consistent with other adherence literature when examining the non-therapeutic 
patients. The majority of patients that were in the non-therapeutic group were 
male with malignant disease. Most pediatric adherence data focuses on 
adolescents. However, in our study, similar to the findings in Phipps and DeCuir-
Whalley (1990), children 1 to 5 years of age also had high levels of non-
therapeutic levels.  
Aim 3: Comparison of standard deviation method and subjective adherence 
The third aim of the study sought to compare the intra-patient standard 
deviations of tacrolimus assays with documented subjective adherence. Again, 
due to the only six episodes of reported patient non-adherence this aim could not 
be completed. However, the 3 patients with documented non-adherence had 
MLVI levels ranging from 1.5 to 3.08.  
Aim 4: Associations between adherence and outcomes 
The final aim of this study was to describe the associations of adherence 
levels with GVHD and readmissions. Subjective adherence could not be 
correlated with these transplant specific adverse outcomes due to small 
numbers. When considered as therapeutic versus non-therapeutic levels in a 
dichotomous fashion, levels were not directly associated with GVHD or 
readmissions. However, as a continuous standard deviation variable and a MLVI 
> 3, was statistically significantly associated with and predictive of GHVD. 
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Readmissions were not statistically significant.  
Summary of results 
 Subjective adherence in pediatric HSCT is often underreported and is 
under recognized. Individual levels do not appear to be associated with or 
predictive of adverse outcomes. A high tacrolimus intra-patient medication level 
variability index (MLVI) has been related to worse outcomes in pediatric liver and 
kidney transplant patients (Rodrigo et al 2016; Shemesh & Fine 2010; Borra et al 
2010; Hsiau et al 2011). The novel MLVI approach used in solid organ transplant 
populations appears to be a promising biomarker that could be used to predict 
adverse outcomes and potential non-adherent patients, however, further study is 
needed. 
Implications 
Although limited by small sample size and retrospective nature, the results 
of this study have several implications for clinical practice and future research. 
These implications are described below.   
Clinical Practice Implications. There is limited data regarding pediatric 
hematopoietic stem cell transplant adherence. Little is known about the depth of 
the problem, contributory facilitators and barriers, as well as the effect on 
outcomes. This study highlights the lack of consistent adherence assessment 
and documentation. Education to providers emphasizing the importance of 
consistently assessing adherence is critical. Often, patient levels outside of the 
therapeutic range are adjusted with no assessment or consideration given to 
level adherence. In addition, when patients develop GVHD, additional 
medications with severe side effects are added without assessing the potential 
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contribution of adherence. Eliminating the escalation of unnecessary medications 
would spare patients further side effects, risk and cost of additional medications. 
Clinically, non-adherence not just to immunosuppressant medications, but 
all necessary post-transplant medications can have serious effects on patients. 
Such adverse effects include GVHD, infections and death. Increased morbidity 
and mortality post-transplant can be a result of non-adherence. Further provider 
awareness of the problem is needed. The ability to identify non-adherence and at 
risk patients, will allow us to begin to develop interventions to aid children and 
their families with strategies for taking the medications as prescribed and 
increase knowledge of risk factors associated with non-adherence. 
 Nurses play a crucial role in the assessment of adherence. As “front-line” 
caregivers, as well as advanced practice providers, consistent assessment and 
education on the importance of adherence is vital to the overall understanding 
and ultimate outcomes of this vulnerable population. Early identification of 
families and children likely non-adherent is key. A further understanding of those 
non-adherent patients and families is critical. Examining risk factors, as well as 
barriers and facilitators is essential to future research in the field.  
Measurement implications. No gold standard for the measurement of 
adherence exists. It is important to recognize adherence is not dichotomous but 
rather a continuum, and identifying what level of non-adherence is dangerous to 
the patient and influences outcomes is crucial. In our small study a s.d. > 3 was 
predictive of GVHD, however further validation of the MLVI as a direct measure 
of adherence is necessary. The results of this study are promising for future 
development of a novel direct measure of adherence. Using the MLVI biomarker 
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that has been established in solid organ transplant could give providers an 
objective measure of adherence and a way to identify at risk patients earlier post-
transplant.  
Recommendations for Future Research 
 Further research in understanding adherence in pediatric hematopoietic 
stem cell transplant is needed. Adherence is not routinely assessed or 
documented at clinic visits. Perhaps it is time for a paradigm shift in clinical care 
to require providers to consider it as a “6th vital sign. Medication reconciliation 
conducted under government regulations is not the same as assessing whether 
patients are receiving the right dose of medication, at the right times, all the time.   
A prospective trial validating and correlating direct and indirect measures 
is crucial. In this study identifying key characteristics, risk factors and potential 
barriers to adherence could not be completed due to the small sample size of 
documented non-adherent patients. Subsequent research will then begin to 
develop intervention trials aimed at increasing adherence to the level needed to 
maintain optimal outcomes in the patients that need them. 
Further exploration of risk factors, specifically age in pediatric stem cell 
transplant, is needed. In both our study and the Phipps and DeCuir-Whalley 
(1990) study, younger age children were at high risk for non-adherence, contrary 
to much of the other adherence literature that focuses on adolescents. We may 
be missing a vulnerable population with unique challenges due to age and 
development. Different, targeted interventions focusing on parents of children in 
the younger age group is needed.  
Measurement. One of the most exciting areas for further research is 
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validation of the novel MLVI biomarker. Further examination of the utility and 
predictability in larger hematopoietic stem cell transplant patients is needed. 
Additional research may test validated subjective reporting measures in 
correlation with the MLVI to better to understand the depth of the problem. 
Because we know that adherence is a continuum, establishing a clinically 
relevant cut-off for adherence and the association of adverse outcomes is crucial.   
Non-adherent patients. Often overlooked, but critical, is a deeper 
exploration of those identified non-adherent patients. A mixed-methods 
approach, relying on focus groups, qualitative interviews, and objective measures 
including the MLVI biomarker would give us a better picture of those at risk 
patients. Qualitative work with non-adherent patients to understand potential 
barriers is key to the future development of intervention trials.  
Theoretical framework. To date, few pediatric adherence studies use a 
theoretical framework to guide the research. Further work in the exploration of 
the Pediatric Self-Management model in this population is necessary. Additional 
theories may exist related to why patients are non-adherent, or more age specific 
theories such as one that explains non-adherence in the 1 to 5 year range may 
be more focused on caregivers or developmental milestones versus decision-
making and self-management in adolescents. Exploration of the prospective 
memory construct and theory could provide rationale for reasons of non-
adherence and guide future research and interventions. 
Conclusions 
This is the first known study to report the use of the novel mediation level 
variability index in hematopoietic stem cell transplant patients. In this study, the 
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MLVI is associated with a known hematopoietic stem cell transplant complication, 
graft versus host disease. The results of this study are encouraging for a new 
potential biomarker to evaluate tacrolimus serum assay levels and identify 
patients at risk for developing GVHD. Future research to develop and further 
validate a novel method of monitoring tacrolimus assays that may be predictive 
of post transplant complications and the relationship to adherence is necessary 
to improve outcomes for children undergoing hematopoietic stem cell transplant.   
There is a significant need for adherence research in the pediatric stem 
cell transplant population. A vast opportunity to conduct further studies and 
address gaps in the body of knowledge exists. Advancing the science through 
exploration of theory, facilitators and barriers, measurement methods, 
correlations to outcomes, as well as interventions research is crucial to overall 
improved outcomes in this vulnerable population. The potential severe 
consequences of poor adherence, such as GVHD, infection and death require 
the transplant community to move adherence research to the forefront. Good 
adherence is fundamental to safe, cost-efficient transplant with optimal long-term 
outcomes.   
 
 
 
 
 
 
 
